These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 15824263

  • 1. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
    Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM.
    Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
    [Abstract] [Full Text] [Related]

  • 2. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
    Ribaï P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, Gasparini F, Charles P, Béraud AS, Schmitt M, Koenig M, Mallet A, Brice A, Dürr A.
    Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
    [Abstract] [Full Text] [Related]

  • 3. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia.
    Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM.
    Ann Neurol; 2001 May; 49(5):590-6. PubMed ID: 11357949
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA.
    J Neurol Sci; 2005 Jun 15; 233(1-2):145-62. PubMed ID: 15896810
    [Abstract] [Full Text] [Related]

  • 6. Neurophysiological evaluation in children with Friedreich's ataxia.
    Sival DA, du Marchie Sarvaas GJ, Brouwer OF, Uges DR, Verschuuren-Bemelmans CC, Maurits NM, Brunt ER, van der Hoeven JH.
    Early Hum Dev; 2009 Oct 15; 85(10):647-51. PubMed ID: 19775837
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
    Lodi R, Tonon C, Calabrese V, Schapira AH.
    Antioxid Redox Signal; 2006 Oct 15; 8(3-4):438-43. PubMed ID: 16677089
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group.
    Arch Neurol; 2007 Jul 15; 64(7):938-44. PubMed ID: 17502459
    [Abstract] [Full Text] [Related]

  • 10. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
    Cooper JM, Schapira AH.
    Mitochondrion; 2007 Jun 15; 7 Suppl():S127-35. PubMed ID: 17485244
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
    Seznec H, Simon D, Monassier L, Criqui-Filipe P, Gansmuller A, Rustin P, Koenig M, Puccio H.
    Hum Mol Genet; 2004 May 15; 13(10):1017-24. PubMed ID: 15028670
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intermediate-dose idebenone and quality of life in Friedreich ataxia.
    Brandsema JF, Stephens D, Hartley J, Yoon G.
    Pediatr Neurol; 2010 May 15; 42(5):338-42. PubMed ID: 20399388
    [Abstract] [Full Text] [Related]

  • 15. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.
    Nachbauer W, Boesch S, Schneider R, Eigentler A, Wanschitz J, Poewe W, Schocke M.
    PLoS One; 2013 May 15; 8(7):e69229. PubMed ID: 23922695
    [Abstract] [Full Text] [Related]

  • 16. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S, Llorens JV, Blanco-Sobero L, Gutiérrez L, Calap-Quintana P, Morales MP, Moltó MD, Martínez-Sebastián MJ.
    Gene; 2013 Jun 01; 521(2):274-81. PubMed ID: 23542074
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities.
    Sparaco M, Gaeta LM, Santorelli FM, Passarelli C, Tozzi G, Bertini E, Simonati A, Scaravilli F, Taroni F, Duyckaerts C, Feleppa M, Piemonte F.
    J Neurol Sci; 2009 Dec 15; 287(1-2):111-8. PubMed ID: 19748629
    [Abstract] [Full Text] [Related]

  • 19. Characterizing gait, locomotor status, and disease severity in children and adolescents with Friedreich ataxia.
    Croarkin E, Maring J, Pfalzer L, Harris-Love M, Siegel K, DiProspero N.
    J Neurol Phys Ther; 2009 Sep 15; 33(3):144-9. PubMed ID: 19809393
    [Abstract] [Full Text] [Related]

  • 20. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease.
    Schapira A, Lodi R.
    Methods Mol Biol; 2004 Sep 15; 277():293-307. PubMed ID: 15201464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.